Alpine Immune Sciences Inc [ALPN] stock prices are up 2.21% to $37.47 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ALPN shares have gain 4.20% over the last week, with a monthly amount glided 35.32%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences. In a post published today on Yahoo Finance, Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences.
From an analyst’s perspective:
Alpine Immune Sciences Inc [NASDAQ: ALPN] stock has seen the most recent analyst activity on February 15, 2024, when Wolfe Research initiated its Outperform rating and assigned the stock a price target of $44. Previously, Berenberg started tracking the stock with Buy rating on October 18, 2023, and set its price target to $18. On October 17, 2023, Berenberg initiated with a Buy rating and assigned a price target of $18 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $19 on October 05, 2023. Morgan Stanley started tracking with a Overweight rating for this stock on January 19, 2023, and assigned it a price target of $17. In a note dated November 21, 2022, SVB Leerink initiated an Outperform rating and provided a target price of $15 on this stock.
The stock price of Alpine Immune Sciences Inc [ALPN] has been fluctuating between $6.39 and $37.03 over the past year. Alpine Immune Sciences Inc [NASDAQ: ALPN] shares were valued at $37.47 at the most recent close of the market.
Analyzing the ALPN fundamentals
The Alpine Immune Sciences Inc [NASDAQ:ALPN] reported sales of 30.80M for trailing twelve months, representing a surge of 20.03%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -2.15%, Pretax Profit Margin comes in at -1.83%, and Net Profit Margin reading is -1.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.32 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 36.48 points at the first support level, and at 35.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 38.24, and for the 2nd resistance point, it is at 39.01.
Alpine Immune Sciences Inc [ALPN] reported earnings per share of -$0.24 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.33/share, meaning a difference of $0.09 and a surprise factor of 27.30%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.27 per share as compared to estimates of -$0.37 per share, a difference of $0.1 representing a surprise of 27.00%.
Ratios To Look Out For
It’s worth pointing out that Alpine Immune Sciences Inc [NASDAQ:ALPN]’s Current Ratio is 3.81. Also, the Quick Ratio is 3.81, while the Cash Ratio stands at 0.37. Considering the valuation of this stock, the price to sales ratio is 79.73, the price to book ratio is 11.42.
Transactions by insiders
Recent insider trading involved Rickey James Paul,, that happened on Jan 26 when 0.12 million shares were sold., Rickey James Paul completed a deal on Jan 25 to sell 236.0 shares. Meanwhile, Director Thompson Peter A. sold 1.36 million shares on Dec 28.
